Schostak Martin, Krause Hans, Miller Kurt, Schrader Mark, Kempkensteffen Carsten, Kollermann Jens
Department of Urology, Charité- Campus Benjamin Franklin, Universitätsmedizin Berlin, Germany.
BJU Int. 2007 Jun;99(6):1409-14. doi: 10.1111/j.1464-410X.2007.06861.x. Epub 2007 Apr 8.
To assess the course of cancer-free survival and thus determine how reliably reverse transcriptase-polymerase chain reaction (RT-PCR) can detect prostate-specific antigen (PSA)-expressing cells, as patients with untreated lymph node-positive prostate cancer tend to have a poor prognosis, whereas those treated with radical prostatectomy (RP) and immediate adjuvant hormonal therapy show excellent local disease control and a disease-free survival comparable with that of patients with negative lymph nodes, but the detection of micrometastatic disease in pelvic lymph nodes remains a major challenge.
Quantitative RT-PCR was used to detect PSA mRNA expression in total RNA of 457 pelvic lymph nodes from 70 patients who had RP (53 patients) or laparoscopic lymphadenectomy (17) at our clinic in 1999/2000. For this purpose, alternate sections of lymph node tissue were either snap-frozen for later RNA isolation or examined by standard histopathological methods. Clinicopathological data, adjuvant treatments and follow-up data were recorded for all patients.
After January 2006 (6-year observation period), 13 patients had no follow-up data, while 27 had biochemical (PSA) recurrence or other evidence of clinical progression (two died from prostate cancer), and 30 had no signs of recurrence. Compared to the 'reference' standard (histopathology), the PCR method had a sensitivity of 83% and a specificity of 66%. The method had a positive predictive value of 52% and a negative predictive value of 57%.
Considered alone, pelvic lymph node PSA RT-PCR does not predict the clinical course better than a histopathological assessment of lymph nodes. However, it also identifies some patients with negative histology who later show progression. When added to the pathological classification, PSA RT-PCR improves the detection rate of primary lymphatic dissemination.
评估无癌生存率的进程,从而确定逆转录聚合酶链反应(RT-PCR)检测表达前列腺特异性抗原(PSA)细胞的可靠性,因为未经治疗的淋巴结阳性前列腺癌患者预后往往较差,而接受根治性前列腺切除术(RP)和即刻辅助激素治疗的患者局部疾病控制良好,无病生存率与淋巴结阴性患者相当,但盆腔淋巴结微转移疾病的检测仍然是一项重大挑战。
采用定量RT-PCR检测1999/2000年在我们诊所接受RP(53例患者)或腹腔镜淋巴结清扫术(17例)的70例患者的457个盆腔淋巴结总RNA中的PSA mRNA表达。为此,淋巴结组织的交替切片要么速冻以备后续RNA分离,要么采用标准组织病理学方法检查。记录所有患者的临床病理数据、辅助治疗和随访数据。
2006年1月后(6年观察期),13例患者无随访数据,27例出现生化(PSA)复发或其他临床进展证据(2例死于前列腺癌),30例无复发迹象。与“参考”标准(组织病理学)相比,PCR方法的敏感性为83%,特异性为66%。该方法的阳性预测值为52%,阴性预测值为57%。
单独考虑,盆腔淋巴结PSA RT-PCR对临床进程的预测并不优于淋巴结的组织病理学评估。然而,它也能识别出一些组织学阴性但后来出现进展的患者。将PSA RT-PCR加入病理分类中,可提高原发性淋巴转移的检测率。